Those who developed procedural AKI also had lower left ventricular ejection fraction at baseline (50.0% vs 56.6%, P = 0.04) and a higher percentage of them were prescribed an angiotensin‐converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) compared to those who did not develop AKI (72.1% vs 53.6%, respectively, P = 0.02) (Table 1). This evidence concerns the gene ACE and acute kidney injury.